Phone Icon

About Our Clinical Trials

Making Strides in Cancer Research Through Clinical Trials

If you're considering participating in a clinical trial, you may feel uncertain and have unanswered questions. At HonorHealth's Virginia G. Piper Cancer Center Clinical Trials program, our team of experts will guide you through the clinical trial process, answer your questions and make recommendations based on your cancer type and unique needs. Then, it's up to you.

You have the opportunity to participate in clinical studies of new cancer treatments through our partnership with Translational Genomics Research Institute (TGen), a leader in developing treatments for complex diseases and genetic studies. HonorHealth serves as a primary clinical research site for TGen, giving you access to investigational treatments in a state-of-the-art facility.

Experience and Expertise

When you participate in our clinical trials, you're in good hands. Our clinical trials research is led by world-renowned cancer physician and researcher Daniel D. Von Hoff, MD, FACP. Dr. Von Hoff is chief scientific officer for HonorHealth's Research Institute and serves as a distinguished professor and physician-in-chief at TGen.

Our team features physicians, scientists, nurse practitioners, nurses and support personnel. Many of these dedicated individuals are considered among the best of their field, and all share a common goal of helping you live a longer and healthier life.

Excellence in Clinical Research

Thanks to our expert team and our participating patients, we're able to develop advanced therapies and innovative procedures, giving our patients access to the latest cancer therapy options sometimes five to 10 years before FDA approval.

Two new cancer treatments first used in patients at the Virginia G. Piper Cancer Center have been approved by the Food and Drug Administration (FDA) in the past two years. This is a significant achievement for any cancer center, much less a community-based center like HonorHealth's. Here are some examples of how our research has been recognized:

  • In September 2013, the FDA approved the combination of Abraxane and Gemcitibine to treat advanced pancreatic cancer. This has since become the new standard of care. The successful international clinical trial was led by HonorHealth researchers.
  • In January 2012, the FDA approved a skin cancer drug tested for the first time in the world at our center. Erivedge, the first drug to receive expedited FDA approval for treating inoperable basal cell carcinoma, went from Phase I clinical trials at our cancer center to FDA approval in five years, half the time it typically takes for a drug to be approved.
  • RADAR (Rapid Detection and Assessment of Response) is a one-of-a-kind rapid cancer detection program developed through collaboration between local physicians, HonorHealth's Research Institute and the Virginia G. Piper Cancer Center. RADAR was a $100,000 grant from the Industrial Development Authority (IDA) of Scottsdale in June 2013.
  • We are one of the original Dream Team sites for cancer research by Stand Up to Cancer, a charity of the Hollywood-based entertainment industry foundation. Our center was the only one in the Southwest participating as a collaborator in the $18 million SU2C pancreatic cancer Dream Team grant. Researchers here have been conducting clinical trials of new treatments designed to cut off the fuel supply of nutrients that feed pancreatic cancer cell growth.
  • Our researchers identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy. The discovery is critical because patients with small-cell lung cancer often do not get a second chance at therapies to combat the aggressive form of cancer.
  • We were the first site in the world for clinical trials of a drug called OSI-906 to combat adrenocortical carcinoma, a rare but deadly cancer that attacks the adrenal glands.
  • We were the world's first clinical trials site for NMS-1286937, a new drug designed to stop cancer from spreading by preventing the process of cell division.

Getting Started

One of our highly experienced oncology nurse navigators will be your personal coordinator, serving as a link between you, your physicians and the clinical trials team to ensure you have the education, support and resources you need.

For more information about clinical trials available at HonorHealth, please contact an oncology nurse navigator at 480-323-1339 or 877-273-3713.